CN109942575A - 作为激酶抑制剂的吡咯并吡啶 - Google Patents

作为激酶抑制剂的吡咯并吡啶 Download PDF

Info

Publication number
CN109942575A
CN109942575A CN201910068067.1A CN201910068067A CN109942575A CN 109942575 A CN109942575 A CN 109942575A CN 201910068067 A CN201910068067 A CN 201910068067A CN 109942575 A CN109942575 A CN 109942575A
Authority
CN
China
Prior art keywords
alkyl
hydrogen
phenyl
base
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910068067.1A
Other languages
English (en)
Chinese (zh)
Inventor
伊万.勒休劳
詹姆斯.F.布莱克
英德拉尼.W.冈瓦达纳
彼得.J.莫尔
埃利.M.华莱士
王斌
马克.奇卡莱利
迈克尔.莱昂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Array Biopharma Inc
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40810786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN109942575(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CN109942575A publication Critical patent/CN109942575A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201910068067.1A 2008-05-13 2009-05-13 作为激酶抑制剂的吡咯并吡啶 Pending CN109942575A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5292608P 2008-05-13 2008-05-13
US61/052,926 2008-05-13
CN200980127299.4A CN102089307B (zh) 2008-05-13 2009-05-13 作为激酶抑制剂的吡咯并吡啶

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200980127299.4A Division CN102089307B (zh) 2008-05-13 2009-05-13 作为激酶抑制剂的吡咯并吡啶

Publications (1)

Publication Number Publication Date
CN109942575A true CN109942575A (zh) 2019-06-28

Family

ID=40810786

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201910068067.1A Pending CN109942575A (zh) 2008-05-13 2009-05-13 作为激酶抑制剂的吡咯并吡啶
CN201510289964.7A Expired - Fee Related CN104926810B (zh) 2008-05-13 2009-05-13 作为激酶抑制剂的吡咯并吡啶
CN200980127299.4A Expired - Fee Related CN102089307B (zh) 2008-05-13 2009-05-13 作为激酶抑制剂的吡咯并吡啶

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201510289964.7A Expired - Fee Related CN104926810B (zh) 2008-05-13 2009-05-13 作为激酶抑制剂的吡咯并吡啶
CN200980127299.4A Expired - Fee Related CN102089307B (zh) 2008-05-13 2009-05-13 作为激酶抑制剂的吡咯并吡啶

Country Status (30)

Country Link
US (6) US8178131B2 (enExample)
EP (2) EP2307409B1 (enExample)
JP (2) JP5703212B2 (enExample)
KR (2) KR101657856B1 (enExample)
CN (3) CN109942575A (enExample)
AR (1) AR071717A1 (enExample)
AU (1) AU2009246402B2 (enExample)
BR (1) BRPI0913580B8 (enExample)
CA (1) CA2724262C (enExample)
CL (1) CL2009001152A1 (enExample)
CO (1) CO6321244A2 (enExample)
CR (1) CR11803A (enExample)
CY (1) CY1116692T1 (enExample)
DK (1) DK2307409T3 (enExample)
ES (1) ES2552643T3 (enExample)
HK (1) HK1219950A1 (enExample)
HR (1) HRP20151018T1 (enExample)
HU (1) HUE026160T2 (enExample)
IL (1) IL209258A (enExample)
MX (1) MX2010012449A (enExample)
NZ (1) NZ589318A (enExample)
PH (1) PH12013501779B1 (enExample)
PL (1) PL2307409T3 (enExample)
PT (1) PT2307409E (enExample)
RS (1) RS54358B1 (enExample)
RU (1) RU2517194C2 (enExample)
SI (1) SI2307409T1 (enExample)
TW (2) TWI554512B (enExample)
UA (1) UA111933C2 (enExample)
WO (1) WO2009140320A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009089352A1 (en) 2008-01-08 2009-07-16 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
JP5608098B2 (ja) 2008-01-09 2014-10-15 アレイ バイオファーマ、インコーポレイテッド キナーゼ阻害薬としてのピラゾロピリジン
JP2009256298A (ja) * 2008-03-26 2009-11-05 Sumitomo Chemical Co Ltd ピペリジン−３−イルカーバメート化合物の光学分割方法およびその中間体
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
SG10201900212QA (en) * 2009-04-11 2019-02-27 Array Biopharma Inc Checkpoint kinase 1 inhibitors for potentiating dna damaging agents
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
US9029359B2 (en) * 2009-09-04 2015-05-12 Biogen Idec Ma, Inc. Heteroaryl Btk inhibitors
JP5749341B2 (ja) 2010-08-20 2015-07-15 ハチソン メディファーマ リミテッド ピロロピリミジン化合物およびその使用
WO2012074754A1 (en) * 2010-11-16 2012-06-07 Array Biopharma Inc. Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors
AU2012254082B2 (en) 2011-02-25 2016-12-08 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
EP2702063A1 (en) 2011-04-29 2014-03-05 Amgen Inc. Bicyclic pyridazine compounds as pim inhibitors
GB201201566D0 (en) * 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
SG11201406818VA (en) 2012-04-23 2014-11-27 Genentech Inc Intermediates and processes for preparing compounds
KR20160104612A (ko) 2013-07-26 2016-09-05 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조성물
CN105705499B (zh) * 2013-08-22 2018-10-12 基因泰克公司 用于制备化合物的方法
WO2015027090A1 (en) * 2013-08-22 2015-02-26 Genentech, Inc. Intermediates and processes for preparing compounds
JP6340416B2 (ja) * 2013-09-25 2018-06-06 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ホスファチジルイノシトール３−キナーゼ−ガンマの選択的インヒビター
AU2015240465B2 (en) 2014-04-04 2020-02-27 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
TW201613919A (en) 2014-07-02 2016-04-16 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
MA41599A (fr) * 2015-02-26 2018-01-02 Array Biopharma Inc Formes cristallines d'un composé pyrrolopyridine
CN107708414B (zh) 2015-06-30 2022-02-25 首尔伟傲世有限公司 适用紫外线发光二极管的捕虫器
RU2765154C2 (ru) * 2015-11-04 2022-01-26 Мерк Патент Гмбх Способы лечения злокачественной опухоли с использованием соединений пиримидина и пиридина с btk ингибирующей активностью
AU2016378579A1 (en) * 2015-12-22 2018-06-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-MLL interaction
KR102436430B1 (ko) 2016-06-10 2022-08-24 비타이 파마슈티컬즈, 엘엘씨 메닌-mll 상호 작용의 억제제
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN112839648B (zh) 2018-06-07 2025-04-04 达萨玛治疗公司 Sarm1抑制剂
JP7566731B2 (ja) * 2018-07-03 2024-10-15 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
CN109053526A (zh) * 2018-08-13 2018-12-21 南通大学 一种（3r，4s）-4-甲基吡咯烷-3-基氨基甲酸叔丁酯盐酸盐的化学合成方法
CN108912032A (zh) * 2018-08-13 2018-11-30 南通大学 一种（3s，4r）-4-甲基吡咯烷-3-基氨基甲醇叔丁酯盐酸盐的化学合成方法
EP3897670A4 (en) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS
WO2020150417A2 (en) 2019-01-17 2020-07-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
JP2023540673A (ja) 2020-07-15 2023-09-26 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
US12152018B2 (en) 2021-01-08 2024-11-26 Ifm Due, Inc. Compounds and compositions for treating conditions associated with STING activity
EP4337203A4 (en) 2021-05-14 2025-04-09 Syndax Pharmaceuticals, Inc. INHIBITORS OF THE MENIN-MLL INTERACTION
CN119798252A (zh) * 2023-10-09 2025-04-11 中国石油化工股份有限公司 一种制备n邻位-酰基取代的含氮杂环化合物及其缩胺合铁(ii)配合物的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1137273A (zh) * 1993-10-14 1996-12-04 艾博特公司 喹嗪酮类化合物
WO2003028724A1 (en) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
WO2005063747A1 (en) * 2003-12-24 2005-07-14 Pfizer Italia S.R.L. PYRROLO[2,3-b] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION COMPRISING THEM
WO2009004329A1 (en) * 2007-07-02 2009-01-08 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
EP1254115A2 (en) 2000-02-11 2002-11-06 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
WO2001079198A1 (en) 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinase
AU2002336462A1 (en) 2001-09-06 2003-03-24 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
US6797825B2 (en) * 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
EP1537106A1 (en) 2002-08-07 2005-06-08 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
AR042667A1 (es) 2002-12-26 2005-06-29 Taisho Pharmaceutical Co Ltd Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico
AU2004220176A1 (en) 2003-03-14 2004-09-23 Astrazeneca Ab Novel fused triazolones and the uses thereof
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
GB0330043D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
EP1756108A2 (en) * 2004-04-02 2007-02-28 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of rock and other protein kinases
EP1737845A4 (en) * 2004-04-13 2010-07-21 Synta Pharmaceuticals Corp DISPLAY HEMMER OF IL-12 PRODUCTION
GB0409080D0 (en) 2004-04-23 2004-05-26 Biofocus Discovery Ltd Compounds which interact with protein kinases
JP2007161585A (ja) 2004-06-25 2007-06-28 Taisho Pharmaceut Co Ltd 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
US20090275570A1 (en) 2005-04-06 2009-11-05 Astrazeneca Ab Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
ES2380795T3 (es) 2005-05-20 2012-05-18 Vertex Pharmaceuticals, Inc. Pirrolopiridinas útiles como inhibidores de proteínas quinasas
JP5220414B2 (ja) * 2005-08-30 2013-06-26 旭化成ファーマ株式会社 スルホンアミド化合物
US7776865B2 (en) 2005-10-06 2010-08-17 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
BRPI0616985B1 (pt) * 2005-10-06 2021-10-26 Merck Sharp & Dohme Corp. Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto
DK3184526T3 (en) 2005-12-13 2019-01-14 Incyte Holdings Corp PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS A JANUS-KINASE INHIBITOR
EP1979353A2 (en) 2006-01-19 2008-10-15 OSI Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
DE102006005179A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Aminoindazolderivate
DE102006005180A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Indazol-heteroaryl-derivate
US20090253718A1 (en) 2006-04-25 2009-10-08 Astex Therapeutics Limited Pharmaceutical Compounds
JP2009536620A (ja) 2006-04-25 2009-10-15 アステックス、セラピューティックス、リミテッド 医薬組み合わせ物
FI3719018T3 (fi) 2006-04-25 2025-10-07 Astex Therapeutics Ltd Puriini- ja deatsapuriinijohdannaisia farmaseuttisina yhdisteinä
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
WO2008075007A1 (en) 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
EA019951B1 (ru) 2007-03-01 2014-07-30 Новартис Аг Ингибиторы киназы pim и способы их применения
JP2011503084A (ja) 2007-11-07 2011-01-27 シェーリング コーポレイション 新規の細胞周期チェックポイント調節剤およびこれらの調節剤とチェックポイント阻害剤との併用
WO2009089352A1 (en) * 2008-01-08 2009-07-16 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
JP5608098B2 (ja) * 2008-01-09 2014-10-15 アレイ バイオファーマ、インコーポレイテッド キナーゼ阻害薬としてのピラゾロピリジン
AR071717A1 (es) * 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
US8481557B2 (en) * 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
US20140221370A1 (en) 2010-07-09 2014-08-07 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
WO2012074754A1 (en) 2010-11-16 2012-06-07 Array Biopharma Inc. Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1137273A (zh) * 1993-10-14 1996-12-04 艾博特公司 喹嗪酮类化合物
WO2003028724A1 (en) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
WO2005063747A1 (en) * 2003-12-24 2005-07-14 Pfizer Italia S.R.L. PYRROLO[2,3-b] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION COMPRISING THEM
WO2009004329A1 (en) * 2007-07-02 2009-01-08 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors

Also Published As

Publication number Publication date
US20160368916A1 (en) 2016-12-22
SI2307409T1 (sl) 2015-11-30
PL2307409T3 (pl) 2016-01-29
BRPI0913580A2 (pt) 2015-10-20
TW201002707A (en) 2010-01-16
EP2990407B1 (en) 2019-10-16
US20130045286A1 (en) 2013-02-21
PH12013501779A1 (en) 2014-08-27
CN104926810A (zh) 2015-09-23
NZ589318A (en) 2011-06-30
US20110070317A1 (en) 2011-03-24
CN102089307A (zh) 2011-06-08
TW201529573A (zh) 2015-08-01
EP2307409B1 (en) 2015-08-12
CY1116692T1 (el) 2017-03-15
RS54358B1 (sr) 2016-04-28
KR20140093266A (ko) 2014-07-25
BRPI0913580B8 (pt) 2021-05-25
US8178131B2 (en) 2012-05-15
KR101657856B1 (ko) 2016-09-19
US9365568B2 (en) 2016-06-14
HUE026160T2 (en) 2016-05-30
US8545897B2 (en) 2013-10-01
US9969727B2 (en) 2018-05-15
IL209258A (en) 2017-01-31
CA2724262A1 (en) 2009-11-19
WO2009140320A1 (en) 2009-11-19
RU2517194C2 (ru) 2014-05-27
HRP20151018T1 (hr) 2015-10-23
US20150322061A1 (en) 2015-11-12
AR071717A1 (es) 2010-07-07
CN102089307B (zh) 2015-07-01
HK1219950A1 (en) 2017-04-21
KR101643426B1 (ko) 2016-07-27
AU2009246402A1 (en) 2009-11-19
AU2009246402B2 (en) 2013-05-23
TWI458727B (zh) 2014-11-01
CL2009001152A1 (es) 2009-10-16
MX2010012449A (es) 2011-05-25
BRPI0913580B1 (pt) 2020-03-10
HK1152035A1 (en) 2012-02-17
DK2307409T3 (en) 2015-09-21
EP2307409A1 (en) 2011-04-13
CN104926810B (zh) 2019-02-19
KR20110008102A (ko) 2011-01-25
CA2724262C (en) 2017-08-15
US8981085B2 (en) 2015-03-17
JP2011520896A (ja) 2011-07-21
US20140243520A1 (en) 2014-08-28
PT2307409E (pt) 2015-11-04
TWI554512B (zh) 2016-10-21
CR11803A (es) 2011-02-11
US20140100369A1 (en) 2014-04-10
CO6321244A2 (es) 2011-09-20
IL209258A0 (en) 2011-01-31
EP2990407A1 (en) 2016-03-02
JP2015098482A (ja) 2015-05-28
PH12013501779B1 (en) 2019-02-13
JP5703212B2 (ja) 2015-04-15
US8758830B2 (en) 2014-06-24
RU2010150786A (ru) 2012-06-20
ES2552643T3 (es) 2015-12-01
UA111933C2 (uk) 2016-07-11

Similar Documents

Publication Publication Date Title
CN104926810B (zh) 作为激酶抑制剂的吡咯并吡啶
RS60468B1 (sr) Nova jedinjenja
TWI762534B (zh) 作為ＰＩ３Ｋδ抑制劑的咪唑並[1,5-A]吡衍生物
KR20160086930A (ko) 피롤로피롤론 유도체 및 bet 억제제로서의 그의 용도
CN106488916A (zh) 作为pde抑制剂的新型2,5‑取代的嘧啶类
AU2013218743B2 (en) Pyrrolopyridines as kinase inhibitors
HK1152035B (en) Pyrrolopyridines as kinase inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190628